Tirzepatide 5mg: what happens at this dose and what to expect next

You've just been told your dose is going up, here's what that actually means

Many people arrive at this question the same way: they have been on 2.5mg for a month, the nausea has mostly settled, and their prescriber is now talking about moving to 5mg. It can feel like both progress and a fresh source of nerves. That reaction is entirely normal.

The 2.5mg pen exists purely to let your body adjust to the medicine, making it the adjustment period rather than the treatment itself. At 5mg, tirzepatide starts activating the GIP and GLP-1 receptors more meaningfully, signalling fullness to the brain, slowing how quickly food leaves the stomach, and beginning to shift the hormonal environment that drives appetite. The NHS tirzepatide patient page describes this dual mechanism and the standard titration schedule clearly if you want a plain-language overview alongside your Patient Information Leaflet.

In practical terms, most people notice appetite suppression becoming more consistent from 5mg onwards. The effect is not uniform (individual response varies) but this is typically the dose where portion sizes start shifting without a conscious effort to restrict them. Weight reduction at 5mg alone is real, though the larger average losses seen in clinical trials came at the higher maintenance doses across the full licensed range.

One thing worth knowing: the full tirzepatide dosing schedule runs from 2.5mg through to 15mg in 2.5mg steps. Whether your treatment stays at 5mg or continues to titrate upward is a clinical decision, not a commercial one. It depends on tolerability, response and your prescriber's assessment at each review.

What the 5mg tirzepatide pen looks like in practice

The Mounjaro 5mg pen is a pre-filled KwikPen. Each pen holds four weekly doses, so a single pen covers one full month of treatment at this strength. You inject subcutaneously (under the skin) into the abdomen, thigh or upper arm, rotating sites each week. The pen is stored in the fridge at 2–8°C; for specific information about how long it can be kept at room temperature before use, the SmPC and your Patient Information Leaflet carry the exact guidance, that window does matter, so it is worth checking rather than guessing.

If you are currently reading about the Mounjaro 5mg pen specifically, the practical details there cover the KwikPen format in more depth. The tirzepatide 5mg pen and the Mounjaro 5mg pen are the same medicine at the same strength, tirzepatide is the active ingredient; Mounjaro is the UK brand name made by Eli Lilly.

GI side effects (nausea, loose stools, constipation, indigestion) are the most commonly reported effects at this stage, as they are across the licensed range. They often become more noticeable after a dose increase than they were mid-pen. For most people they settle within a few days to two weeks. Staying well hydrated and eating smaller, lower-fat meals during that adjustment window tends to help. If symptoms are severe or persistent, that is a conversation for your prescriber, not something to wait out indefinitely.

Who reaches 5mg, and when the decision is made to go higher

Under the licensed UK schedule, tirzepatide is titrated every four weeks, or more slowly if tolerance requires it, with doses adjusted in steps until you reach the level where meaningful benefit and acceptable tolerability meet. The goal is to reach the dose where you are getting meaningful benefit without unacceptable side effects. For some people that is 5mg. For others, treatment continues up through 7.5mg, 10mg, 12.5mg or 15mg. The NICE technology appraisal for tirzepatide (TA1026) notes that if less than 5% weight loss has been achieved after six months at the highest tolerated dose, continuing treatment should be reviewed, which underlines why the dose titration process matters and why it is led by a prescriber rather than self-managed.

Private eligibility for licensed tirzepatide treatment in adults broadly follows the medicine's UK licence: BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or raised cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI figures alone never tell the whole story, a prescriber looks at the full picture.

For context on what the private treatment pathway looks like overall, our weight-loss treatment overview sets out how the clinical assessment works and what is included. If you are weighing up the cost side of things, this page on Mounjaro pricing in the UK separates what is typically included in a headline price from what sometimes is not, worth a read before comparing providers. And if you are ready to find out whether you are eligible, checking your eligibility with our prescribers is the natural next step.